<DOC>
	<DOCNO>NCT00772486</DOCNO>
	<brief_summary>The study Phase 1b open label , non-randomized , single institution clinical trial design evaluate safety tolerability three repeat infusion ISF35 follow standard regimen three cycle fludarabine , cyclophosphamide rituximab ( FCR ) subject refractory , resistant , and/or 17p- CLL .</brief_summary>
	<brief_title>A Phase Ib Study ISF35 Combination With Chemotherapy ( FCR ) Subjects With Relapsed , Refractory , and/or 17p- CLL</brief_title>
	<detailed_description>ISF35 already use two Phase I clinical trial . The trial demonstrate ISF35 treatment well tolerated patient experience significant unexpected adverse event . Patients report flu-like symptom ISF35 , disappear within one three day . The trial also show ISF35 stimulates immune system act CLL cell sensitize leukemic cell subsequent treatment . Repeat infusion ISF35 administer single agent subject CLL result durable reduction circulate lymph-node bound leukemic cell . Furthermore , CLL patient 17p deletion respond standard course FCR receive ISF35 achieve durable remission . ISF35 abbreviation Immune Stimulatory Factor 35 , offspring technology discover Dr. Thomas J. Kipps , MD , PhD , Professor , Department Medicine Deputy Director Research , UCSD Moores Cancer Center .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects must diagnosis B cell CLL include : Lymphocytosis monoclonal Bcells coexpressing ≥ one Bcell marker ( CD19 , CD20 , CD23 ) CD5 peripheral blood lymph node AND Bone marrow ≥ 30 % mononuclear cell CLL/SLL phenotype 2 . Measurable disease , least one IWCLL 2008 Guidelines `` Indications Treatment '' follow : Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia . Massive ( i.e. , &gt; 6 cm leave costal margin ) progressive asymptomatic splenomegaly . Massive node ( i.e. , &gt; 10 cm long diameter ) progressive symptomatic lymphadenopathy . Progressive lymphocytosis increase &gt; 50 % 2month period , lymphocyte doubling time ( LDT ) less 6 month . LDT obtain linear regression extrapolation absolute lymphocyte count ( ALC ) obtain interval two week observation period 23 month ; patient initial blood lymphocyte count less 30,000 per microliter may require long observation period determine LDT . Also , factor contribute lymphocytosis lymphadenopathy CLL ( e.g , infection ) exclude . Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy . A minimum one follow diseaserelated symptom must present : Unintentional weight loss ≥10 % within previous 6 month . Significant fatigue ( i.e. , ECOG PS 2 worse ; work unable perform usual activity ) . Fevers great 100.5 degree F 38.0 degree C 2 week without evidence infection . Night sweat 1 month without evidence infection . Hypogammaglobulinemia monoclonal oligoclonal paraproteinemia constitute basis initiate treatment . 3 . Subjects must CLL document resistant refractory standard chemotherapy regimens contain alkylating agent and/or purine analogue . Chemotherapy refractory resistant define follow : CLL progression treatment ( 2 cycle ) chemotherapy ; OR Failure achieve PR CR least 2 cycle chemotherapy ; OR No response treatment stable disease least 2 cycle chemotherapy ; OR Disease progression within 6 month treatment chemotherapy ; OR CLL cytogenetic change document loss short arm chromosome 17 ( 17p ) associate loss p53 . 4 . Subjects must age 18 year old 5 . For men woman childbearing potential , use effective barrier contraceptive method study one month follow treatment 6 . Subjects must ECOG performance scale ≤ 2 7 . Subjects must adequate hematologic , renal , hepatic , coagulation function define : • Adequate hematologic function : ) Platelet count ≥ 50,000/µL ; AND ii ) Hemoglobin ≥ 10 g/dL ( may support erythropoietin transfusion ) ; AND • Adequate renal function : ) Calculated creatinine clearance ≥ 30 mL/min/1.73 m^2 ; OR ii ) Serum creatinine ≤ 2 time upper limit normal ; AND • Adequate hepatic function : ) Total bilirubin ≤ 2.5 time upper limit normal ; AND ii ) ALT ≤ 2.5 time upper limit normal ; AND • Adequate coagulation test : ) Prothrombin time international normalize ratio ( INR ) ≤ 1.5 ; AND ii ) Partial thromboplastin time ≤ 1.5 time upper limit normal 8 . Ability understand requirement study , provide write informed consent authorization use disclosure protect health information , agree abide study restriction return required assessment Exclusion Criteria 1 . Presence &gt; 55 % prolymphocytes Richter 's transformation 2 . Chemotherapy ( e.g. , purine analogue , alkylating agent , corticosteroid ) , antibody therapy , immunotherapy , radiation therapy , participation investigational drug treatment within 4 week enrollment protocol time study 3 . Ongoing toxicity prior antineoplastic therapy 4 . Untreated autoimmune hemolytic anemia immune thrombocytopenia 5 . Active symptomatic fungal , bacterial and/or viral infection include active HIV viral ( A , B C ) hepatitis 6 . Positive serology HIV1,2 HTLV I , II 7 . CMV disease positive DNA PCR 8 . Syphilis positive VDRL 9 . Acute Hepatitis A C positive serology , Hepatitis B , acutely chronically infect base CDC criterion 10 . Any illness condition opinion investigator may affect safety treatment evaluation study 's endpoint</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Lymphocytic , Chronic , B-Cell</keyword>
	<keyword>Leukemia , B-Cell</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>ISF35</keyword>
	<keyword>Ad-ISF35</keyword>
	<keyword>Refractory</keyword>
	<keyword>Resistant</keyword>
	<keyword>17p-</keyword>
	<keyword>del 17p</keyword>
	<keyword>17p</keyword>
	<keyword>Resistant CLL</keyword>
	<keyword>Refractory CLL</keyword>
	<keyword>17p- CLL</keyword>
	<keyword>CLL</keyword>
</DOC>